Stocktoria
Surrozen, Inc./DE SRZN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-11-23
Surrozen, Inc./DE financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.5M | $10.7M | $0 | $12.5M | $0 |
| R&D expense | $29.4M | $21.1M | $27.2M | $37.0M | $40.2M |
| Operating income | -$42.1M | -$25.5M | -$45.8M | -$44.3M | -$54.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$242.0M | -$63.6M | -$43.0M | -$36.0M | -$54.6M |
| EPS (diluted) | $-32.37 | $-21.67 | $-21.33 | $-15.56 | $-2.21 |
| Operating cash flow | -$30.2M | -$17.6M | -$40.4M | -$44.1M | -$48.8M |
| Free cash flow | -$30.4M | -$17.7M | -$40.8M | -$44.9M | -$50.1M |
| Cash & equivalents | $89.2M | $34.6M | $36.0M | $24.7M | $33.1M |
| Total assets | $98.7M | $48.5M | $46.1M | $89.4M | $137.2M |
| Total liabilities | $286.5M | $69.8M | $8.1M | $13.4M | $27.5M |
| Shareholders' equity | -$187.8M | -$21.4M | $37.9M | $76.0M | $109.7M |
Source: SEC EDGAR filings · CIK 0001824893 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.